Andere Sprachen Athira Pharma, Inc.

Aktien

A2QCFW

US04746L1044

ATHA

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 19.04.2024			% 5 Tage	% 1. Jan.
2.13 ^USD	+3.40%		-12.70%	-12.35%

15.04.	Athira Pharma, Inc. ernennt Javier San Martin, M.D., zum Chief Medical Officer	CI
11.04.	Athira Pharma, Inc. gibt die Veröffentlichung von präklinischen Daten bekannt, die die Behandlung mit Fosgonimeton in Modellen der Alzheimer-Krankheit unterstreichen	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer	15.04.
Athira Pharma, Inc. Appoints Javier San Martin, M.D., as Chief Medical Officer	15.04.
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's disease	12.04.
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease	11.04.
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease	11.04.
Athira Pharma, Inc. Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease	11.04.
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting	03.04.
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference	08.03.
Athira Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22.02.
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates	22.02.
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)	08.02.
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)	08.02.
Athira Pharma, Inc. Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis	08.02.
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update	08.01.
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update	08.01.
Athira Pharma, Inc. Provides 2024 Clinical Pipeline Outlook	08.01.
Athira Pharma, Inc. Announces Hans Moebius Retires as Chief Medical Officer	08.01.
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease	03.01.
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease	03.01.
Athira Pharma, Inc. Completes Enrollment of Phase 2/3 Lift-AD Clinical Trial of Fosgonimeton in Mild-To-Moderate Alzheimer's Disease	03.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Athira Pharma, Inc.

Aktien

A2QCFW

US04746L1044

ATHA

Andere Sprachen

Filter